Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Neuroinflammation and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TSPO/PBR drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TSPO/PBR Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Ideal for standard ELISA screening. |
View TSPO Products |
| Gene Delivery | TSPO/PBR Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Preserves native 5-transmembrane conformation. |
View TSPO Products |
| Benchmark Ab | Anti-TSPO/PBR Recombinant Antibody Recombinant positive control for assay validation. |
View TSPO Products |
| Validator | TSPO/PBR siRNA Set For knockdown verification in target specificity assays. |
View TSPO Products |
| Related Target A | TREM2 Key microglial receptor modulating neuroinflammation; synergistic with TSPO activation pathways. |
View TREM2 Products |
| Related Target B | NLRP3 Downstream inflammasome complex linked to mitochondrial ROS and TSPO-mediated cell death. |
View NLRP3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multi-pass Membrane Conformation (5-TM) | Lentivirus Premade Particles optimized for stable cell line generation to preserve native 5-TM conformation. |
| Species Cross-Reactivity (Human vs. Rodent) | Human, Mouse, and Rat ortholog lentiviral constructs strictly sequence-verified. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay calibration. |
| False Positives in Binding Assays | Validated siRNA sets included for target knockdown and specificity validation. |
Live TSPO/PBR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TSPO/PBR therapeutics is intensifying, with major players shifting focus from traditional diagnostics (PET tracers) to small molecule modulators targeting neurodegenerative diseases. As first-generation imaging agents reach clinical maturity, the next wave of R&D is targeting TSPO-mediated mitochondrial transition pore regulation to treat neuroinflammation, microglial activation, and neurooncology indications.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Modulators | Acadia Pharmaceuticals, AlzeCure Pharma | Alzheimer's Disease, Parkinson's Disease | Cell-based binding assays (Need TSPO overexpressing stable cell lines via Lentivirus) |
| PET Radiotracers | GE Healthcare, Roche, Academic Consortia | Neuroinflammation, Glioma Imaging | High-affinity validation (Need sequence-verified TSPO mutant/wild-type constructs) |
| Targeted Therapeutics | Biotech Startups | Glioblastoma, Neuroinflammation | Specificity validation (Need TSPO knockdown via siRNA and homolog screening) |